$16.92▴ 0.12%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
32th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+15.0%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Theravance Biopharma, Inc.'s earnings-quality signal is not available yet. Revenue is growing strongly year over year. Its valuation is around the middle of its own recent range.
Key numbers
Valuation
EPS (TTM)$2.20
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin104.3%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$109.78M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.